Compounded Semaglutide in 2026: What's Still Available

This week, two of the largest national 503B compounding facilities — ProRx Pharmaceuticals and BPI Labs — announced they are halting production of compounded GLP-1 medications. For patients who depend on affordable compounded semaglutide, this is alarming news. But it is not the end of the road — yet.

Compounded semaglutide is still available as of April 2026, primarily through 503A pharmacies operating under patient-specific prescriptions. Pricing currently ranges from $147 to $269 per month depending on dose and provider. But the supply chain is visibly narrowing, and this article exists to give you a clear-eyed picture of what is actually available, what is not, and what to watch out for as the market gets more chaotic.

What Is Happening: The 503B Exit

To understand why this week's news matters, you need to understand the two-tier compounding landscape that has existed for the past two years.

The FDA's compounding framework distinguishes between 503A pharmacies (traditional, patient-specific compounders regulated primarily at the state level) and 503B outsourcing facilities (larger commercial manufacturers operating under FDA current Good Manufacturing Practices). When semaglutide landed on the FDA shortage list in 2022, both tiers could legally compound it. 503B facilities like ProRx and BPI became the backbone of the telehealth compounding supply chain — filling prescriptions written by thousands of online prescribers at scale.

Both ProRx and BPI announced this week they are ceasing GLP-1 production. This follows regulatory pressure that has intensified significantly since the FDA's April 22, 2026 deadline for 503A pharmacies to stop compounding semaglutide (since the drug shortage has been officially resolved). For 503B facilities, the calculus shifted: continued production without shortage justification exposes them to significant enforcement risk. The economics no longer work.

The exits matter because these two facilities were supplying a large portion of the telehealth compounding market. The downstream effect: telehealth platforms that relied on these suppliers are now scrambling to find alternative 503B partners, and many are finding few viable options remain.

503A vs. 503B: The Plain English Version

This distinction matters for your options, so it is worth being clear about it.

• 503A pharmacies are traditional compounders. They require a valid prescription from a licensed prescriber for a specific patient. They operate under state pharmacy board oversight plus federal rules. They cannot produce large batches speculatively. Their products are not FDA-approved, but they operate in a long-standing legal framework.
• 503B outsourcing facilities are FDA-registered manufacturers operating under cGMP standards. They can produce larger batches, do not always require patient-specific prescriptions, and are subject to direct FDA inspections. They were the source for most telehealth-at-scale compounding operations.

The key practical difference right now: the 503A pathway is still open for semaglutide — barely. The FDA's April 22 ban applied to 503A pharmacies, but there is an ongoing legal challenge (filed by the Outsourcing Facility Association and others) that has created regulatory uncertainty. Some 503A pharmacies continue filling prescriptions pending litigation outcomes. This is the gray area where pricing in the $147–$269/mo range currently exists.

503B facilities, by contrast, are largely exiting voluntarily or under enforcement pressure. The risk-reward has inverted.

What Is Still Available: Compounded Semaglutide in April 2026

Despite the headline pressure, compounded semaglutide has not fully disappeared. Here is the real landscape:

503A pharmacies with active prescriptions remain the primary source. These are state-licensed compounding pharmacies that, in jurisdictions where pending litigation has created legal cover, continue filling patient-specific prescriptions. Prices have risen from the $99–$140/mo lows of 2023–2024, but are still meaningfully below brand-name costs.

Availability is not universal. It depends on: the state you live in, whether your prescriber has a relationship with a 503A pharmacy that is still filling, and whether that pharmacy has continued production pending litigation. Patients in states with more restrictive pharmacy boards may find their access has already closed.

The legal uncertainty creates a window — but not a guarantee. If the ongoing court challenges fail, the 503A pathway closes entirely. If they succeed, the window may stay open longer. No one can tell you with confidence which way the courts will go.

Tirzepatide Compounding: Why It Is Effectively Over

If you were on compounded tirzepatide — the active ingredient in Mounjaro and Zepbound — your situation is categorically different and worse.

The FDA removed tirzepatide from the drug shortage list in March 2025. That removal triggered an immediate ban on 503A compounding, which took effect without the same legal ambiguity that has kept semaglutide's situation more fluid. The 503A pathway for tirzepatide is closed. No major 503B facilities are producing it either — the regulatory risk is simply too high post-shortage.

What this means practically: compounded tirzepatide is not available through legitimate pharmacies at this time. If you are seeing advertisements for "compounded tirzepatide" from online providers, those claims warrant serious scrutiny. Either the pharmacy is operating in a legally precarious position, or the product is not what it claims to be.

For tirzepatide patients, the realistic options are brand-name Zepbound or Mounjaro with insurance, manufacturer savings cards (Eli Lilly has offered these), or transitioning to semaglutide-based options while access to those still exists.

Brand-Name Alternatives: The Real Costs

Let us be honest about the numbers, because too many articles gloss over this part.

• Ozempic (semaglutide, 0.5–2mg): Retail list price approximately $935–$970/month. With insurance coverage for Type 2 diabetes indication, significantly lower or free. Without insurance and without obesity indication: full cost.
• Wegovy (semaglutide, 0.25–2.4mg): Retail list price approximately $1,349/month. With commercial insurance for obesity: $25–$100/month for many plans. Without coverage: full cost. Novo Nordisk's savings card program can reduce this for commercially insured patients.
• Rybelsus (oral semaglutide, 3–14mg): Approved for Type 2 diabetes, not obesity. List price around $900/month. The oral form has somewhat lower bioavailability than injectable — not a direct dose equivalent.
• Mounjaro (tirzepatide, diabetes indication): List price approximately $1,023/month. Eli Lilly savings cards available for commercially insured patients ($25/month with eligible insurance).
• Zepbound (tirzepatide, obesity indication): List price approximately $1,059/month. Self-pay vials program available directly from Eli Lilly at reduced cost; check Zepbound.com for current pricing.

The self-pay landscape is brutal without insurance. The gap between $175/month compounded semaglutide and $1,349/month brand Wegovy is not a rounding error — it is the difference between affordable and impossible for many patients.

The one meaningful bright spot: Eli Lilly launched a direct-to-patient self-pay vials program for Zepbound that currently prices some doses significantly below the retail list price. This is worth checking if tirzepatide is your preference and insurance is not viable. Do not rely on any third party for current pricing — check the manufacturer's website directly.

Telehealth Options: The Current Landscape

Telehealth has been the primary distribution channel for compounded GLP-1s, and the platforms are in a transitional state right now.

Some larger telehealth platforms that relied on 503B suppliers like ProRx and BPI are actively scrambling to replace their pharmacy relationships. Some have moved to 503A-based fulfillment; others have pivoted toward brand-name prescribing with discount facilitation. The patient experience varies significantly by platform right now — what was available from a given provider two weeks ago may not be available today.

If you are actively looking for a prescription path to compounded semaglutide, the practical steps are:

1. Ask the telehealth provider explicitly: "Which pharmacy will fill my prescription, and is it a 503A or 503B?" A provider that cannot answer this is a red flag.
2. Ask whether the pharmacy is currently filling under ongoing litigation or a formal legal exception. Vague answers here also warrant caution.
3. Verify the pharmacy's license with your state pharmacy board. This is publicly searchable in most states.
4. Confirm the product has a Certificate of Analysis (COA) from a third-party lab. Legitimate 503A pharmacies provide these on request.

Red Flags and Quality Risks in a Narrowing Market

When supply narrows and consumer anxiety spikes, predatory actors fill the gap. This market is no exception.

Watch out for these specifically:

• Suspiciously low prices. If someone is advertising compounded semaglutide for $59/month in April 2026, the math does not work for a legitimate 503A pharmacy. That price point is a signal to investigate, not celebrate.
• Overseas or "research chemical" sourcing. Semaglutide sold as a "research peptide" from overseas suppliers is not pharmaceutical-grade. It has not been manufactured under cGMP standards, it has not been tested for sterility or potency, and it is not legal for human use in this context. The risks are real and serious.
• Providers who cannot name their pharmacy. If a telehealth company will not tell you which pharmacy fills your prescription, walk away.
• No COA, no physician review, prescription rubber-stamping. Legitimate GLP-1 prescribing involves a real clinical assessment. Async-only platforms with no actual prescriber interaction are cutting corners that matter for your safety.
• Unusual formulations or additives. Some compounders began adding B12, L-carnitine, or other additives to differentiate products. Ask what is in your formulation. Additives have not been studied in combination with semaglutide in clinical trials.

What Is Likely to Happen Next

This section involves uncertainty, and we will state our reasoning rather than present speculation as fact.

Semaglutide's 503A window: The legal challenges to the FDA ban are active. Historically, courts have given significant deference to FDA drug shortage determinations. The most likely outcome over the next 3–6 months is that the litigation fails and the 503A pathway closes entirely for semaglutide. A court victory for the challengers would extend access meaningfully, but that outcome is uncertain.

Pricing pressure on brand-names: The entry of oral semaglutide (Wegovy Oral was approved in late 2025), combined with growing political pressure around drug pricing, creates conditions for some brand-name price movement. Generic semaglutide is not expected in the U.S. market until Novo Nordisk's patents begin expiring — the earliest meaningful patent cliff is around 2032.

Insurance coverage expansion: The Medicare coverage expansion for obesity-indication GLP-1s (part of the Inflation Reduction Act discussions) remains politically contested. Expansion would dramatically improve access for Medicare patients. Commercial insurer coverage for weight management GLP-1s continues to expand slowly — roughly 40% of commercial plans now cover obesity-indication GLP-1s with prior authorization.

New entrants: Oral small-molecule GLP-1 agonists from multiple manufacturers are in Phase 2 and 3 trials. If approved, these would create genuine competition that changes the pricing landscape. That timeline is 2–4 years out at minimum.

The honest summary: patients who relied on compounded GLP-1s at $100–$200/month are facing a structural access problem, not a temporary disruption. The window is still open for semaglutide through 503A pharmacies, but it is narrowing. If you are currently on compounded semaglutide, now is the time to discuss insurance coverage and brand-name options with your prescriber — not as a fallback, but as an active plan.

Frequently Asked Questions